Prestudy patient treatment histories
| Characteristic . | Data . |
|---|---|
| Disease classification at study entry, no. (%) | |
| T-ALL | 26 (67) |
| T-LBL | 13 (33) |
| No. of prior courses of induction therapy (%) | |
| 1 prior course | 11 (28) |
| More than 1 prior course | 28 (72) |
| Response to most recent prior therapy, n (%) | |
| Relapsed after CR | 20 (51) |
| Refractory | 19 (49) |
| Number of prior multiagent regimens excluding surgery | |
| Median (range) | 2 (1-5) |
| 1, no. (%) | 11 (28) |
| 2, no. (%) | 10 (26) |
| 3, no. (%) | 9 (23) |
| 4, no. (%) | 7 (18) |
| 5, no. (%) | 2 (5) |
| Prior high-dose methotrexate, no. (%) | 9 (23) |
| Prior high-dose cytarabine, no. (%) | 25 (64) |
| Prior irradiation, no. (%) | 19 (49) |
| Prior stem cell transplant, no. (%) | 5 (13) |
| Characteristic . | Data . |
|---|---|
| Disease classification at study entry, no. (%) | |
| T-ALL | 26 (67) |
| T-LBL | 13 (33) |
| No. of prior courses of induction therapy (%) | |
| 1 prior course | 11 (28) |
| More than 1 prior course | 28 (72) |
| Response to most recent prior therapy, n (%) | |
| Relapsed after CR | 20 (51) |
| Refractory | 19 (49) |
| Number of prior multiagent regimens excluding surgery | |
| Median (range) | 2 (1-5) |
| 1, no. (%) | 11 (28) |
| 2, no. (%) | 10 (26) |
| 3, no. (%) | 9 (23) |
| 4, no. (%) | 7 (18) |
| 5, no. (%) | 2 (5) |
| Prior high-dose methotrexate, no. (%) | 9 (23) |
| Prior high-dose cytarabine, no. (%) | 25 (64) |
| Prior irradiation, no. (%) | 19 (49) |
| Prior stem cell transplant, no. (%) | 5 (13) |